PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ocugen

Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

May 15, 2024

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital...

April 14, 2023

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

May 24, 2022

PharmaShots Weekly Snapshots (December 27- 31, 2021)

PharmaShots Weekly Snapshots (December 27- 31, 2021)

December 31, 2021

Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

December 31, 2021

PharmaShots Weekly Snapshots (July 05 - 09, 2021)

PharmaShots Weekly Snapshots (July 05 - 09, 2021)

July 9, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us